Sean Bohen - Dec 9, 2024 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Signature
/s/ Shane Kovacs, Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Dec 9, 2024
Transactions value $
-$986,365
Form type
4
Date filed
12/11/2024, 07:52 PM
Previous filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Award $0 +205K +139.84% $0.00 351K Dec 9, 2024 Direct F1, F2
transaction OLMA Common Stock Sale -$490K -52.3K -14.9% $9.37 299K Dec 10, 2024 Direct F3, F4
transaction OLMA Common Stock Sale -$484K -55.9K -18.71% $8.66 243K Dec 11, 2024 Direct F3, F5
transaction OLMA Common Stock Sale -$11.9K -1.27K -0.52% $9.39 242K Dec 11, 2024 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 315,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria.
F2 Includes 1,489 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024.
F3 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F4 The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.87 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.